NASDAQ:AXSM
Axsome Therapeutics Stock News
$74.89
+1.13 (+1.53%)
At Close: May 01, 2024
3 Surefire Stocks to End 2022 on a Good Note
06:00am, Saturday, 10'th Dec 2022
These stocks should help your portfolio shine now and well into the future.
Axsome: More Catalysts Stacking For 2023
12:05pm, Thursday, 08'th Dec 2022
In its early launch for depression, Axsome Therapeutics, Inc.'s Auvelity is already garnering robust market adoption. Demonstrating its therapeutic prowess, Auvelity also recently reported superb data
12 Top Stocks to Buy in December
05:57am, Saturday, 03'rd Dec 2022
Add this dandy dozen to your stocking this month.
Axsome Therapeutics Stock: Bear vs. Bull
10:15am, Friday, 02'nd Dec 2022
2023 will almost certainly see Axsome's top line explode higher.
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
08:44am, Wednesday, 30'th Nov 2022
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
02:18pm, Tuesday, 29'th Nov 2022
Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.
Why Is Axsome Therapeutics (AXSM) Stock Up 32% Today?
12:35pm, Monday, 28'th Nov 2022
Axsome Therapeutics (NASDAQ: AXSM ) stock is soaring higher on Monday after releasing positive results from a Phase 3 clinical trial. That Phase 3 clinical trial covers Alzheimer's Disease drug candid
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
09:07am, Monday, 28'th Nov 2022
Biogen stock toppled Monday after a report suggested its experimental Alzheimer's treatment caused a patient's fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimer's Death While Axsom
Axsome's stock rallies 15% on promising findings for its experimental Alzheimer's drug
08:36am, Monday, 28'th Nov 2022
Shares of Axsome Therapeutics Inc. AXSM, +1.07% jumped 15.5% in premarket trading on Monday after the company said its Alzheimer's treatment candidate met the primary and secondary endpoints in a Phas
Want to Double Your Money? Buying These Stocks Could be a Genius Move
06:00am, Monday, 28'th Nov 2022
These stocks are undervalued considering their long-term growth potential.
3 Growth Stocks to Buy That Could Skyrocket
05:55am, Monday, 28'th Nov 2022
The future looks promising for all three of these stocks.
Prediction: This Growth Stock Could Double in 2023
09:45am, Thursday, 24'th Nov 2022
The next year should be a busy one for this drugmaker.
Axsome: Strong Earnings Signal More Upside
02:40am, Thursday, 24'th Nov 2022
As Auvelity is recently approved, Axsome now has two solid drugs that are likely to generate significant market traction. Toward year-end, Axsome will report data of the ACCORD trial that further woul
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
07:00am, Wednesday, 23'rd Nov 2022
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
06:30am, Sunday, 20'th Nov 2022
Innovative products and services could keep these companies growing.
